Literature DB >> 24700715

Many roads lead to MPN.

Heike L Pahl1.   

Abstract

In this issue of Blood, Lundberg et al correlate the presence of known mutations in patients with myeloproliferative neoplasms (MPNs) with clinical outcome, thereby proposing a molecular risk stratification.

Entities:  

Mesh：

Year:  2014        PMID： 24700715      PMCID： PMC3975254          DOI： 10.1182/blood-2014-02-554709

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Impact of genetic features on treatment decisions in AML.

Authors:  Hartmut Döhner; Verena I Gaidzik
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.

Authors:  Guido Marcucci; Torsten Haferlach; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

3.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

Authors:  Amy V Jones; Andrew Chase; Richard T Silver; David Oscier; Katerina Zoi; Y Lynn Wang; Holger Cario; Heike L Pahl; Andrew Collins; Andreas Reiter; Francis Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

4.  Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

Authors:  Francis H Grand; Claire E Hidalgo-Curtis; Thomas Ernst; Katerina Zoi; Christine Zoi; Carolann McGuire; Sebastian Kreil; Amy Jones; Joannah Score; Georgia Metzgeroth; David Oscier; Andrew Hall; Christian Brandts; Hubert Serve; Andreas Reiter; Andrew J Chase; Nicholas C P Cross
Journal:  Blood       Date:  2009-04-22       Impact factor: 22.113

5.  JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.

Authors:  Isabelle Plo; Mayuka Nakatake; Laurent Malivert; Jean-Pierre de Villartay; Stéphane Giraudier; Jean-Luc Villeval; Lisa Wiesmuller; William Vainchenker
Journal:  Blood       Date:  2008-05-30       Impact factor: 22.113

6.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Authors:  Pontus Lundberg; Axel Karow; Ronny Nienhold; Renate Looser; Hui Hao-Shen; Ina Nissen; Sabine Girsberger; Thomas Lehmann; Jakob Passweg; Martin Stern; Christian Beisel; Robert Kralovics; Radek C Skoda
Journal:  Blood       Date:  2014-01-29       Impact factor: 22.113

7.  MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Authors:  Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

8.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

9.  MPN patients harbor recurrent truncating mutations in transcription factor NF-E2.

Authors:  Jonas S Jutzi; Ruzhica Bogeska; Gorica Nikoloski; Corina A Schmid; Thalia S Seeger; Frank Stegelmann; Sven Schwemmers; Albert Gründer; Jan C Peeken; Monika Gothwal; Julius Wehrle; Konrad Aumann; Kamar Hamdi; Christine Dierks; Wei Kamar Wang; Konstanze Döhner; Joop H Jansen; Heike L Pahl
Journal:  J Exp Med       Date:  2013-05-06       Impact factor: 14.307
  9 in total
  1 in total

Review 1.  Epigenetics in Myeloproliferative Neoplasms.

Authors:  Suzanne McPherson; Mary Frances McMullin; Ken Mills
Journal:  J Cell Mol Med       Date:  2017-07-04       Impact factor: 5.310
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.